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 The ﬁeld of interstitial lung disease (ILD) has undergone 
signiﬁcant evolution in recent years, with an increasing 
incidence and more complex, ever expanding disease 
classiﬁcation. In their most severe forms, these diseases lead 
to progressive loss of lung function, respiratory failure and 
eventually death. Despite notable advances, progress has 
been challenged by a poor understanding of pathological 
mechanisms and patient heterogeneity, including variable 
progression. The diagnostic pathway is thus being continually 
reﬁned, with the introduction of tools such as transbronchial 
cryo lung biopsy and a move towards genetically aided, 
precision medicine. In this review, we focus on how to 
approach a patient with ILD and the diagnostic process. 
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 Introduction 
 Interstitial lung disease (ILD) is an umbrella term for over 
200 different diseases that display considerable variation in 
terms of clinical course, treatment and prognosis. Broadly 
speaking, they can be subdivided into those with an identifiable 
cause and those without; the latter being referred to as 
idiopathic interstitial pneumonias. Clinical assessment aims 
to identify a possible cause; screening for features of systemic 
disease (eg connective tissue disease) or environmental triggers. 
Relevant exposures include pneumotoxic drugs, radiation 
therapy, occupational exposures (eg asbestosis) or implicated 
allergens (hypersensitivity pneumonitis). 
 Distinguishing the various forms of pulmonary fibrosis is 
critical for determining correct management and for predicting 
prognosis; however, this is often obfuscated by the fact the lung 
has a limited repertoire in response to injury and, consequently, 
a finite number of disease patterns. In essence, all ILD is 
characterised by variable degrees of inflammation and fibrosis, 
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not only between diseases, but also among individuals with 
the same disease (Fig  1 ). In inflammation dominant disease, 
the histology is that of organising pneumonia or non-specific 
interestitial pneumonitis, while in fibrosis dominant disease, 
one would expect to see usual interstitial pneumonitis (UIP) 
– characterised by fibroblastic foci and only mild to moderate 
inflammation. These histological patterns are associated with 
specific radiological features, the recognition of which may 
abrogate the need for a formal biopsy and tissue diagnosis. 
 Idiopathic pulmonary ﬁbrosis 
 Idiopathic pulmonary fibrosis (IPF) is the most common of 
the idiopathic interstitial pneumonias, with an incidence of 
approximately 6,000 cases per year in the UK, affecting mainly 
older males. Median survival is worse than many cancers at 
just 3 years and the disease accounts for 5,300 deaths each year 
in the UK . 1 IPF is a growing problem, with an annual increase 
in incidence of 11% between 1991 and 2003, a rise that is only 
partly explained by an ageing population. 2 
 As already alluded to, distinguishing IPF from other ILDs, 
including other idiopathic forms, is important for multiple 
reasons. IPF does not respond to immunosuppressive therapy; 
in fact, immunomodulation may worsen outcomes. 3 By 
contrast there is evidence, particularly in systemic sclerosis 
associated ILD, 4 of benefit from cyclophosphamide and 
mutliple case reports suggest a potential role for rituximab 5 as 
salvage therapy in connective tissue disease-ILD. In addition, 
there are now two drugs, pirfenidone and nintedanib, approved 
by the National Institute for Health and Care Excellence 
(NICE) for IPF; however, at an annual cost of around £26,000 
per patient and the potential for significant side effects, accurate 
disease identification is essential. Finally, IPF has a worse 
prognosis than other ILD; therefore, a definitive diagnosis 
allows for timely involvement of palliative care physicians and 
consideration of lung transplantation. 
 Pathogenesis of idiopathic pulmonary ﬁbrosis 
 The pathogenesis of IPF is complex and poorly understood, 
but involves aberrant wound healing in the context of 
repetitive alveolar injury. This results in abnormal fibroblast 
proliferation, differentiation and activation, which in turn 
drives expansion of the extracellular matrix with loss of normal 
lung architecture. Inflammation plays a less dominant role. 
This pathogenesis is illustrated schematically in  Fig 2. 
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 Fig 2.  The pathogenesis of idiopathic pulmonary ﬁ brosis. 1 – In an initiating phase, there is lung alveolar epithelial damage with loss of the normal 
lung architecture and disruption of the basement membrane across which gas exchange takes place. With further epithelial damage and apoptosis, 
comes upregulation of epithelial integrins, such as αvβ6, and a phase of ﬁ broproliferative repair dominates – driven by high levels of TGF-β. Released in 
an inactive form, this cytokine requires an activation step facilitated by integrins that bind the Arg-Gly-Asp (arginine-glycine-aspartic acid; RGD) motif of 
pro-TGFβ and promote its cleavage and activation. 2 – Locally activated TGF-β drives the recruitment of ﬁ broblasts and a feed-forward cycle of further 
TGF-β production. 3 – Under these conditions, ﬁ broblasts differentiate into myoﬁ broblasts that express high levels of integrin αvβ6, are resistant to 
apoptosis and lay down a collagen matrix. 4 – Once collagen has been laid down in a lung, the architecture of which is already distorted, gas exchange is 
no longer efﬁ cient. There is a change in the vasculature of the lung parenchyma with both fall-out of blood vessels and neo-angiogenesis driven by local 
production of vascular endothelial and platelet derived growth factors (VEGF and PDGF). At this ﬁ nal phase, the lung is irreversibly scarred .
AEC = alveolar epithelial cell; PDGF = platelet-derived growth factor; TGF-β = transforming growth factor beta; TNF-α = tumour necrosis factor alpha; 
VEGF = vascular endothelial growth factor. 
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Fig 1.  Schematic classiﬁ cation 
of interstitial lung diseases 
according to aetiology. The ﬁ nding 
of histological usual interstitial 
pneumonitis in a patient with an 
idiopathic interstitial pneumonia 
leads to the speciﬁ c diagnosis of 
idiopathic pulmonary ﬁ brosis .
NSIP = non-speciﬁ c interstitial 
pneumonitis. 
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 Genetics in diagnosis and management of idiopathic 
pulmonary ﬁbrosis 
 Although the initiating events in IPF are poorly understood, 
the disease is likely to be the result of environment exposures in 
genetically susceptible individuals. Certainly, it is estimated that 
approximately 20% of idiopathic interstitial pneumonias have 
a genetic component and familial cases (referred to as familial 
interstitial pneumonias) were first described in the 1950s. The 
majority of these familial interstitial pneumonias are autosomal 
dominant with incomplete penetrance, but some may arise 
 de novo . The most commonly affected genes are those involved in 
surfactant processing and telomere biology. At present, routine 
genetic testing is not recommended; however, ILD patients with 
at least one affected first degree relative should be offered the 
opportunity to enrol in the UK-wide 100,000 Genomes Project, 
whereby they undergo whole genome sequencing. 
 Genetics also have a proven role in sporadic IPF. 
Polymorphisms in the promoter for the gene encoding the 
salivary mucin, 5b (MUC5B) and for the Toll-interacting 
protein (TOLLIP) are both associated with an increased risk 
of developing IPF, although both result in a relatively mild 
phenotype. These genetic variants provide the first possible 
targets for precision medicine in IPF, with a post hoc analysis of 
the PANTHER data establishing a variable response to N-acetyl 
cysteine depending on the individual's TOLLIP genotype. 6 
 Diagnostic work up in interstitial lung diseases 
 Initial investigations include blood tests to detect the presence 
of autoantibodies (Table  1 ), precipitating immunoglobulins 
against organic antigens and serum angiotensin-converting 
enzyme. These tests alone rarely confirm the diagnosis and there 
is potential for both false positive (particularly autoantibodies in 
older patients) and false negative (failure to identify an antigen 
and IgG does not exclude hypersensitivity pneumonitis) results; 
however, they can be useful in helping direct further diagnostics . 
 Pulmonary function tests are key in appraising these patients 
and while they rarely refine the specific diagnosis in individuals 
with proven ILD, they inform on disease severity at baseline 
and response to treatment over follow up . 
 Radiological work up 
 Chest radiographs 
 A chest X-ray is often the first radiological investigation in ILD 
patients and while it is rarely sufficient to make a confident 
diagnosis, X-ray can play a role in establishing disease 
chronicity and progression. 
 High-resolution computerised tomography 
 High-resolution computerised tomography (HRCT) of the 
thorax has revolutionised the diagnosis and classification 
of ILD and, in many cases, removes the need for invasive 
diagnostic procedures. However, the quality of the images is 
dependent on the scanning protocol employed (Box 1). 
 The American Thoracic Society/European Respiratory Society 
(ATS/ERS) 2011 consensus statement 7 provides criteria for a 
definite UIP pattern on HRCT (Fig  3 ), with the presence of 
these conferring a sensitivity of approximately 40%, but a 
specificity of 95% for histological UIP. The main discriminating 
feature for UIP is the presence of honeycombing; however, 
typical CT appearances are only present in two thirds of 
patients and it is in the remaining third of cases that biopsy may 
have a role. 
 Table 1.  Autoantibodies in connective tissue ILDs 
Antibody Associated connective tissue disease 
ANA (>1:320) Many
RF (>60 IU/mL) 
Anti-CCP
RA, Sjögren’s syndrome, SLE 
RA
Anti-centromere Systemic sclerosis
Anti-nuclear ANA Systemic sclerosis
Anti Ro (SS-A) SLE, Sjögren’s syndrome and others
Anti La (SS-B) SLE, Sjögren’s syndrome
Anti-RNP SLE, MCTD
Anti-dsDNA SLE
Anti-Smith SLE
Anti tRNA synthetase Poly-/dermatomyositis (anti-synthetase 
syndrome)
Anti-PM-Scl Systemic sclerosis/myositis overlap
Anti-Th/To Systemic sclerosis
Anti-U3 RNP Systemic sclerosis
ANCA panel Vasculitides
Anti-topoisomerase (Scl-70) Systemic sclerosis
 ANA = antinuclear antibody; ANCA = Anti-neutrophil cytoplasmic antibodies; 
Anti-CCP = anti-cyclic citrullinated peptide antibody; anti-dsDNA = anti-double 
stranded DNA; anti-PM-Scl = anti polymyositis-scleroderma; anti-RNP = anti-
ribonucleoprotein; ILD = interstitial lung disease; MCTD = mixed connective 
tissue disease; RA = rheumatoid arthritis; RF = Rheumatoid Factor; SLE = 
systemic lupus erythematosus 
 Box 1.  The ATS/ERS consensus statement for the 
diagnosis of IPF set out criteria for the optimal 
HRCT technique for evaluation of ILD 1 
 Optimal HRCT technique for evaluation of ILD 
 >  Non-contrast scans obtained on full inspiration without 
respiratory motion. 
 >  Contiguous or non-contiguous axial scans with thin sections, 
reconstructed at ≤2 cm intervals. 
 >  Reconstructed slice collimation ≤2 mm. 
 >  High resolution reconstruction algorithm. 
 >  Field of view to include lungs only. 
 >  Expiratory scans are helpful to exclude lobular air trapping 
suggestive of hypersensitivity pneumonitis. 
 >  Prone scans if dependent density obscures detail on supine 
images. 
 >  Optional coronal and sagittal reconstructions if volumetric 
images are obtained. 
 ATS = American Thoracic Society; ERS = European Respiratory Society; 
HRCT = high resolution computerised tomography; ILD = interstitial lung 
disease; IPF = idiopathic pulmonary fibrosis 
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 Bronchoscopy in the assessment of interstitial lung 
disease 
 Bronchoalveolar lavage, endobronchial ultrasound and 
transbronchial biopsy 
 There is much variation in practice surrounding the use of 
bronchoalveolar lavage (BAL), particularly between European 
centres who, in contrast to their North American colleagues, 
often perform this investigation routinely. Clearly, there is value 
in excluding infection, which may be a differential diagnosis; 
however, BAL alone is rarely diagnostic, with perhaps one of 
the difficulties being a lack of consistency in terms of how 
samples are taken and processed. Under optimal circumstances, 
BAL reflects cellular traffic in the alveolar space and the cell 
differential may provide supplemental information to help 
refine, rather make a diagnosis. In particular, an excess of 
lymphocytes should call into question a presumptive IPF 
diagnosis, with Ohshimo  et al 8 describing a BAL lymphocytosis 
of >30% in 6 of 74 patients with definite UIP features on HRCT. 
In all six cases, further investigations led to a final diagnosis of 
chronic hypersensitivity pneumonitis. 
 Transbronchial biopsy (TBB) with standard forceps is a 
minimally invasive technique, but does not always provide 
adequate lung tissue to establish a final diagnosis. The biopsies are 
small, subject to crush artefact and may not be representative in 
spatially heterogeneous disease. 9,10 However, such biopsies may be 
helpful in the diagnosis of sarcoidosis and organising pneumonia. 
 Transbronchial cryo lung biopsy 
 Transbronchial cryo lung biopsy (TBCLB) was first described in 
2008. 11 It has since been shown to be a safe, minimally invasive 
and effective diagnostic tool for the histological diagnosis 
of ILD, with a diagnostic yield of up to 74–80%. 11–15 The 
advantage of TBCLB over TBB lies in the larger specimen size, 
with a mean size of 9–64 mm 2 . 11–20 In addition, the technique 
avoids crush or bleeding artefact, which can distort the tissue 
architecture (Fig  4 ). The published data on TBCLB shows a 
safety profile that is comparable to TBB, with bleeding post 
biopsy in around 10% of cases, all of which was controlled 
bronchoscopically. The mean rate of pneumothorax requiring 
chest drain insertion is around 4%, although there is a wide 
variation between centres. Exacerbations of ILD are rare (0.5%) 
and only one mortality has been reported (0.2%). 11–20 
 Pajares  et al 14 conducted a prospective randomised trial 
comparing TBCLB with TBB and demonstrated a mean 
specimen size for TBCLB samples of 14.7 mm 2 (versus 3.3 mm 2 
for TBB biopsy, p<0.001), resulting in a histological diagnosis 
in 74.4% of patients versus 34.2% in the TBB group (p<0.001). 
When comparing this technique with surgical lung biopsy 
there are various potential advantages. General anaesthesia 
is not necessary and the procedure can be performed as a day 
case with uncomplicated cases returning home the same day. 
Future clinical trials and an increase in real world experience of 
TBCLB is likely to cement its use for selected cases, potentially 
reducing the number of surgial lung biopsies performed. 
 Surgical lung biopsy 
 Surgical lung biopsies are the current gold standard for 
obtaining histological material in the diagnosis of clinically and 
radiologically unclassifiable ILD. It is usually performed via 
the less invasive video-assisted thoracoscopic surgical (VATS) 
approach. As previously described, using the criteria set out in 
the 2011 ATS/ERS consensus statement, about two thirds of 
IPF cases can be diagnosed on the basis of typical clinical and 
radiological findings of UIP (Fig  5 ); however, only 7.5–12% 
of suspected IPF patients undergo surgical lung biopsy in the 
UK. 21 This reflects clinicians’ reluctance to refer patients for a 
procedure associated with a significant mortality and morbidity. 
 The average hospital stay associated with VATS biopsy 
is 2–4 days, 22 with mortality rates of 3–4% and an overall 
complication rate of up to 16%. 23 Common complications 
include persistent air leak, exacerbations of underlying ILD due 
to mechanical stress of single lung ventilation, bleeding and 
delayed wound healing. In addition, 57% of patients report pain 
 Fig 4.  Comparison between transbronchial cryo lung biopsy (A) and 
traditional forceps transbronchial biopsy (B) performed on the same 
patient at two different sittings. Transbronchial cryo lung biopsy shows 
preserved architecture of parenchymal tissue with a total biopsy area 
of 46.81 mm 2 and mean biopsy area of 11.7 mm 2 . Traditional forceps 
transbronchial biopsy is characterised by crush and haemorrhagic artefact 
with a total biopsy area of 14.11 mm 2 and mean biopsy area of 2.8 mm 2 . 
 Fig 3.  Diagnostic criteria for a deﬁ nite usual interstitial pneumonitis 
pattern on high resolution computerised tomography. 1 – subpleural, 
basal predominance (red arrows); 2 – reticular abnormality (blue arrow); 
3 – honeycombing with or without traction bronchiectasis (yellow arrow); 
4 – absence of features inconsistent with usual interstitial pneumonitis pattern. 
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Paent with suspected IPF
Are there any idenﬁable causes of ILD?
No
Possible UIP or inconsistent with UIP
Not UIP on biopsy
Yes
UIP, probable UIP, possible UIP or
non-classiﬁable ﬁbrosis
Deﬁnite
UIP paern
Biopsy (surgical or potenally transbronchial cryo lung biopsy) 
What paern is the histology consistent with?
MDT review and intercalaon of HRCT and biopsy data
Deﬁnite IPF
Not IPF
What is the HRCT paen consistent with?
HRCT Biopsy Diagnosis
Possible UIP UIP or probable IPF
Possible UIP Not UIP Not IPF
Inconsistent UIP Possible IPF
Inconsistent Probably, possible,
non-classiﬁable
Not IPF
Possibly UIP Possible or non-classiﬁable Probable IPF
 Fig 5.  Diagnostic algorithm for idiopathic pulmonary ﬁ brosis, in part adapted from the ATS/ERS consensus statement. HRCT = high-resolution 
computerised tomography; ILD = interstitial lung disease; IPF = idiopathic pulmonary ﬁ brosis; UIP = usual interstitial pneumonitis 
at the incision site 6–12 months after surgery. 24 It is also worth 
remembering that surgical lung biopsy does not guarantee a 
definite pathological diagnosis, with diagnosis rates ranging 
from 34–100%. 22,23 
 Multidisciplinary team 
 Taking into consideration the various investigations involved 
in ILD diagnosis it is clear that no single diagnostic test 
can provide a confident answer. A consensus approach by a 
multidisciplinary team (MDT) with expertise in ILD is thus 
considered the gold standard (Fig  6 ). The MDT integrates 
all available data at several stages of the work up. This not 
only improves inter-observer agreement and diagnostic 
confidence, but may also prevent unnecessary surgical biopsies, 
while identifying patients in whom a biopsy may effectively 
contribute to the diagnosis. 25 Current NICE guidelines 
recommend that IPF should only be diagnosed by MDT 
consensus and stipulates a minimum MDT composition. 26 
 Novel therapies in idiopathic pulmonary ﬁbrosis 
 There has been a dramatic increase in clinical trial activity in 
IPF in recent years, with the discovery and approval of two new 
anti-fibrotic drugs (pirfenidone and nintedanib) heralding a 
new era in the disease. While these novel anti-fibrotic agents 
have been shown to slow the decline in forced vital capacity 
(FVC), they neither halt progression nor reverse existing fibrosis. 
In part because of considerable cost, their use is restricted by 
NICE to patients fulfilling certain criteria – namely a predicted 
FVC of 50–80%, thereby excluding patients at each extreme of 
the disease process and those with spuriously maintained FVC 
due to concurrent emphysema. Given these restrictions, as well 
as the limitations of these therapies, the importance of non-
pharmacological therapy, such as pulmonary rehabilitation, plus 
the enrolment of patients into clinical trials (Fig  7 ) should not be 
underestimated. 
 Novel biomarkers 
 The need to distinguish the different idiopathic interstitial 
pneumonias has driven the search for novel diagnostic 
biomarkers. In addition, there are marked survival differences 
even within specific groups, such as IPF. Biomarkers that can 
identify these phenotypes are needed for clinical decision 
making, but they also have the potential to aid cohort 
enrichment in clinical trials. Previous landmark studies have 
beautifully illustrated this need, with variable rates of decline 
in placebo arms leading to inconsistent results and a delay in 
drugs being approved. 21 
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 Fig 6.  The role of specialist 
multidisciplinary teams and 
specialist referral centres in the 
diagnosis and management of 
interstitial lung disease . 
CTD = connective tissue disease; 
ILD = interstitial lung disease; 
IPF = idiopathic pulmonary ﬁ brosis; 
LAM = lymphangioleiomyomatosis; 
LCH = Langerhans cell histiocytosis; 
MDT = multidisciplinary team; 
NSIP = non-speciﬁ c interstitial 
pneumonitis 
ILD diagnosis
made
HRCT reviewed
by MDT ± BAL/biopsy
Inial assessment
Follow-up
assessments
Manage acute exacerbaons*
> anbiocs
> steroids
> ancoagulaon
If IPF or other progressing ILD
> palliave care
> venlaon decisions
> advance direcves
Treatment opons considered
Pharmacological:
> speciﬁc depending on disease
   subtype
> symptom control
Non-pharmacological:
> oxygen (if indicated)
> pulmonary rehab
Assess comorbidies:
> GOR
> PHT
If features suggest high
mortality risk, transplant review
Assess disease progression
3–6 monthly review, clinical
and PFTs
Discussion with
transplant
physicians – detailed
assessment, if
appropriate
Paent considered for and made aware of clinical trials
 Fig 7.  Schematic interstitial lung disease treatment algorithm. *No robust evidence for managing exacerbations with variation between centres, 
should be discussed with specialist centre if possible. BAL = bronchoalveolar lavage; GOR = gastro-oesophageal reﬂ ux; HRCT = high-resolution computerised 
tomography; ILD = interstitial lung disease; IPF = idiopathic pulmonary ﬁ brosis; MDT = multidisciplinary team; PFT = pulmonary function test; PHT = 
pulmonary hypertension 
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 To date, efforts have focused on serum biomarkers 27 that 
are relatively easy to access and novel imaging modalities 
that potentially inform on disease activity within the lung. 
In particular, positron emission tomography (PET) allows 
non-invasive measurement of cellular metabolism  in vivo . The 
 18 F-fluorodeoxyglucose ( 18 F-FDG) PET signal is consistently 
raised in ILD 28 and is both stable and reproducible (Fig  8 ). 
In a population of over 200 ILD patients, we have shown that 
baseline measures of  18 F-FDG uptake on PET are related to 
patient survival in both IPF and other idiopathic interstitial 
pneumonias (unpublished data). High pulmonary  18 F-FDG 
uptake is associated with poor survival, giving additional 
information to pulmonary function testing and, thus, 
could become a valuable part of the initial work up in newly 
diagnosed patients. 
 Conclusion 
 The diagnosis of ILD is a challenging and involved process. It 
relies on detailed history taking and the integration of various 
investigations and specialties. The relative rarity of these 
diseases makes distinguishing subtypes even more difficult for 
clinicians with a mixed respiratory case workload and, thus, 
infrequent exposure to ILD. Having said this, the incidence of 
ILD is increasing and there is potential for specialist centres 
to become overwhelmed with patients, putting a greater 
than ever emphasis on collaboration with referring centres 
and a concerted effort to employ a hub and spoke model. 
This has the added advantage of facilitating a more patient-
centred approach, minimising the need for unnecessary 
travel and facilitating access to ancillary local services, such 
as pulmonary rehab, oxygen providers and palliative care 
services. 
 Irrespective of expertise, uncertainty is inherent in the 
diagnosis of these diseases, although arguably encountering 
ILD on a frequent basis allows the physician to become more 
comfortable with these uncertainties, thus embracing the 
concept of continuous diagnostic review. The hope remains 
that, in time, reliable, non-invasive biomarkers will identify 
disease subtypes, predict prognosis and potentially replace the 
need for biopsy. Much of the heterogeneity seen in IPF may 
be explained by the existence of endotypes, in other words, 
mechanistically different disease subtypes, which consequently 
exhibit very different responses to therapy. Therefore, future 
treatments have the potential to be greatly influenced by 
identifying these groups through the use of genetic testing and 
a move towards personalised disease management. ■ 
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